In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kadmon Gene Therapy Holdings Ltd.

Latest From Kadmon Gene Therapy Holdings Ltd.

Pipeline Watch: Phase III Progress With Bempedoic Acid, Lefamulin, And Ibrutinib Combo

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

Deals Shaping The Medical Industry, June 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2015.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Kadmon Gene Therapy Holdings Ltd.
  • Senior Management
  • Alexandria Forbes, PhD, CEO
  • Contact Info
  • Kadmon Gene Therapy Holdings Ltd.
    1 Fetter Lane
    London, EC4A 1BR
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register